Drug Trial Radar · NCT07374419
Atamparib in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
178
Planned (sponsor's estimate)
Start
Mar 18, 2026
Primary completion
Jul 31, 2028
Study completion Jan 31, 2029
Sponsor
- Lead sponsor
- Nerviano Medical Sciences (Shanghai) Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) adenocarcinoma. The study comprises dose escalation (phase Ib) and expansion (phase II).
Conditions
- NSCLC Adenocarcinoma
- Solid Tumor
Interventions
atamparib escalation levelsDrug
Bid, Oral, escalating at different dose levels
atamparib RP2DDrug
Bid, oral, RP2D
Primary outcomes
What the sponsor says the trial is designed to measure.
- RP2D and MTDTime frame: 28 days after the last dose
- Type, incidence and severity of adverse eventTime frame: until 28 days after the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Unit 3.53, 3rd Floor, No. 5, Lane 720 Cailun Road, Pilot Free Trade Zone, Shanghai, P.R.China
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.